Value of MRI biliary score and liver/muscle ratio in evaluating the pathological grade of liver fibrosis

Lu HUANG; Lijian LU

doi:10.12449/JCH240413

Volume 40 Issue 4

Apr. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(4): 720-725

PDF( 1168 KB)

Value of MRI biliary score and liver/muscle ratio in evaluating the pathological grade of liver fibrosis

DOI: 10.12449/JCH240413

Lu HUANG¹,
Lijian LU^{2
,
,
,}

1.
Department of Infectious Diseases，The First Affiliated Hospital of Guangxi Medical University，Nanning 530021，China
2.
Department of Radiology，Wuming Hospital Affiliated to Guangxi Medical University，Nanning 530199，China

Research funding:

Guangxi Medical and Health Appropriate Technology Development and Promotion and Application Project (S2020045)

More Information

Corresponding author: LU Lijian， lulijiannet@163.com （ORCID： 0000-0002-5605-9031）
Received Date: 2023-07-06
Accepted Date: 2023-08-18
Published Date: 2024-04-25

Abstract

Abstract

Objective To investigate the value of biliary score and hepatic signal intensity-to-muscle signal intensity ratio （HMR） obtained by multiphase contrast-enhanced MRI scan using Gd-EOB-DTPA in evaluating the pathological grade of liver fibrosis. Methods A retrospective analysis was performed for the MRI and clinical data of 51 patients with chronic hepatitis B liver fibrosis in Wuming Hospital Affiliated to Guangxi Medical University from January 2020 to May 2023. The 51 patients with liver fibrosis were divided into low-grade group （S1-S2） and high-grade group （S3-S4）. GE Architact 3.0T MR scanner was used to perform MRI scans， including routine plain scan and contrast-enhanced scan at arterial phase， portal venous phase， delayed phase， hepatobiliary phase， and excretory phase， and biliary score and HMR were measured for the patients with different grades of liver fibrosis. The t-test was used for comparison of continuous data between groups， and the chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups. The receiver operating characteristic （ROC） curve was plotted to evaluate the value of MRI indicators in determining the pathological grade of liver fibrosis. Results Among the 51 patients with liver fibrosis， there were 30 patients in the low-grade group and 21 in the high-grade group. Compared with the high-grade group， the low-grade group had significantly higher biliary score （3.67±0.55 vs 2.57±0.75， t=6.05， P<0.001） and HMR at portal venous phase （2.38±0.76 vs 1.97±0.18， t=2.41， P=0.020）， delayed phase （2.48±0.70 vs 1.99±0.27， t=3.09， P=0.003）， and hepatobiliary phase （4.10±0.63 vs 3.16±0.47， t=5.81， P<0.001）. The above indicators had an area under the ROC curve （AUC） of 0.86， 0.79， 0.82， and 0.88， respectively， in distinguishing low- and high-grade liver fibrosis， with a positive rate of 70%， 63.3%， 83.3%， and 96.7%， respectively， and a negative rate of 90%， 95.2%， 74.1%， and 100%， respectively， in the diagnosis of high-grade liver fibrosis. Biliary score combined HMR had an AUC of 0.95， with a positive rate of 85.7% and a negative rate of 96.7%. Conclusion Biliary score and HMR at hepatobiliary phase obtained by multiphase contrast-enhanced MRI scan using Gd-EOB-DTPA has a relatively high diagnostic efficacy in distinguishing between low- and high-grade liver fibrosis and a certain guiding value for the diagnosis and treatment of liver fibrosis in clinical practice.
- Hepatic Fibrosis,
- Magnetic Resonance Imaging,
- Gadolinium Plug Acid Disodium

FullText(HTML)

References(18)

References

[1]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35( 10): 2163- 2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35( 10): 2163- 2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
[2]	GUO JS. The critical importance of diagnosing and treating liver fibrosis[J]. J Clin Hepatol, 2018, 34( 1): 16- 19. DOI: 10.3969/j.issn.1001-5256.2018.01.002. 郭津生. 重视肝纤维化的诊治[J]. 临床肝胆病杂志, 2018, 34( 1): 16- 19. DOI: 10.3969/j.issn.1001-5256.2018.01.002.
[3]	BEDOSSA P, DARGÈRE D, PARADIS V. Sampling variability of liver fibrosis in chronic hepatitis C[J]. Hepatology, 2003, 38( 6): 1449- 1457. DOI: 10.1053/jhep.2003.09022.
[4]	LI MB, LI JY, FENG DP. Research advances in the reversal of liver fibrosis[J]. J Clin Hepatol, 2023, 39( 1): 193- 198. DOI: 10.3969/j.issn.1001-5256.2023.01.030. 李满彪, 李金玉, 冯对平. 肝纤维化逆转的研究进展[J]. 临床肝胆病杂志, 2023, 39( 1): 193- 198. DOI: 10.3969/j.issn.1001-5256.2023.01.030.
[5]	LI ZC, HUANG Y, ZHANG ZY, et al. Analysis of prediction indicators and prediction model construction for severity of liver fibrosis[J]. Chin J Gen Surg, 2020, 29( 11): 1364- 1369. DOI: 10.7659/j.issn.1005-6947.2020.11.010. 李哲成, 黄云, 张泽宇, 等. 肝纤维化严重程度预测指标分析与预测模型构建[J]. 中国普通外科杂志, 2020, 29( 11): 1364- 1369. DOI: 10.7659/j.issn.1005-6947.2020.11.010.
[6]	DONG SQ, MA QZ, WU CN, et al. Imaging quality of biliary tract and detecting diseases with hepatobiliary phase Gd-EOB-DTPA contrast-enhanced MR cholangiography based on 3D-VIBE and 3D-FLASH sequences[J]. Chin J Med Imag Technol, 2023, 39( 6): 866- 871. DOI: 10.13929/j.issn.1003-3289.2023.06.015. 董思情, 马巧稚, 吴春楠, 等. 3D-VIBE与3D-FLASH序列肝胆特异期Gd-EOB-DTPA增强MR胆道成像显示胆道系统图像质量及检出病变[J]. 中国医学影像技术, 2023, 39( 6): 866- 871. DOI: 10.13929/j.issn.1003-3289.2023.06.015.
[7]	DU WT, REN WL, HU DD, et al. Research progress on reversible animal model of liver fibrosis[J/OL]. Chin J Liver Dis Electron Version, 2022, 14( 3): 18- 21. DOI: 10.3969/j.issn.1674-7380.2022.03.005. 杜文涛, 任万雷, 胡豆豆, 等. 肝纤维化可逆转动物模型研究进展[J/OL]. 中国肝脏病杂志(电子版), 2022, 14( 3): 18- 21. DOI: 10.3969/j.issn.1674-7380.2022.03.005.
[8]	DEWIDAR B, MEYER C, DOOLEY S, et al. TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019[J]. Cells, 2019, 8( 11): 1419. DOI: 10.3390/cells8111419.
[9]	LIU JH, LI XY, WANG ML, et al. Advantages and characteristics of traditional Chinese medicine in the treatment of liver fibrosis[J]. J Clin Hepatol, 2023, 39( 2): 267- 272. DOI: 10.3969/j.issn.1001-5256.2023.02.003. 刘俊宏, 李欣瑜, 王淼蕾, 等. 中医药治疗肝纤维化的优势与特色[J]. 临床肝胆病杂志, 2023, 39( 2): 267- 272. DOI: 10.3969/j.issn.1001-5256.2023.02.003.
[10]	LU LG, YOU H, XIE WF, et al. Consensus on the diagnosis and therapy of hepatic fibrosis[J]. J Pract Hepatol, 2019, 22( 6): 793- 803. 陆伦根, 尤红, 谢渭芬, 等. 肝纤维化诊断及治疗共识(2019年)[J]. 实用肝脏病杂志, 2019, 22( 6): 793- 803.
[11]	SUN YM, CHEN SY, YOU H. Regression of liver fibrosis: Evidence and challenges[J]. Chin Med J, 2020, 133( 14): 1696- 1702. DOI: 10.1097/CM9.0000000000000835.
[12]	TONG HF, WANG ZH, CHEN H, et al. Prediction of the histological grades of liver fibrosis and cirrhosis by quantitative analysis of gadoxetic acid contrast-enhanced MRI[J]. J Wenzhou Med Univ, 2020, 50( 9): 717- 722. DOI: 10.3969/j.issn.2095-9400.2020.09.006. 童洪飞, 王兆洪, 陈辉, 等. 定量分析钆塞酸二钠增强MRI预测肝纤维化和肝硬化病理分级[J]. 温州医科大学学报, 2020, 50( 9): 717- 722. DOI: 10.3969/j.issn.2095-9400.2020.09.006.
[13]	JIANG Y, SHU J, LU X, et al. A preliminary study for the quantitative assessment of chronic hepatitis by dynamic contrast-enhanced magnetic resonance imaging[J]. J Clin Radiol, 2019, 38( 7): 1324- 1329. DOI: 10.13437/j.cnki.jcr.20190731.014. 蒋颖, 舒健, 卢欣, 等. 钆塞酸二钠DCE-MRI定量评估慢性肝炎的初步研究[J]. 临床放射学杂志, 2019, 38( 7): 1324- 1329. DOI: 10.13437/j.cnki.jcr.20190731.014.
[14]	ZHANG JY, LU J, ZHANG XQ, et al. Feasibility and repeatability of Gd-EOB-DTPA enhanced MRI in evaluating hepatic function[J]. J Nantong Univ Med Sci, 2021, 41( 6): 534- 538. DOI: 10.16424/j.cnki.cn32-1807/r.2021.06.013. 张继云, 陆健, 张学琴, 等. Gd-EOB-DTPA增强MRI评估肝段肝功能的可行性及可重复性研究[J]. 南通大学学报(医学版), 2021, 41( 6): 534- 538. DOI: 10.16424/j.cnki.cn32-1807/r.2021.06.013.
[15]	WANG AR, WANG Q. The Current status of gadolinium disodium enhanced MRI in quantitative assessment of liver function[J]. Chin J Oncol Prev Treat, 2021, 13( 1): 94- 99. DOI: 10.3969/j.issn.1674-5671.2021.01.18. 王安荣, 王强. 钆塞酸二钠增强MRI在定量肝功能评估的应用现状[J]. 中国癌症防治杂志, 2021, 13( 1): 94- 99. DOI: 10.3969/j.issn.1674-5671.2021.01.18.
[16]	Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association. Consensus on clinical application of transient elastography detecting liver fibrosis: A 2018 update[J]. Chin J Hepatol, 2019, 27( 3): 182- 191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004. 中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会, 等. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27( 3): 182- 191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
[17]	IMAJO K, KESSOKU T, HONDA Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography[J]. Gastroenterology, 2016, 150( 3): 626- 637.e7. DOI: 10.1053/j.gastro.2015.11.048.
[18]	LIU YR, WANG M, ZENG G, et al. Diagnostic efficacy of significant liver fibrosis by apparent diffusion coefficient in patients with primary sclerosing cholangitis[J]. J Pract Hepatol, 2021, 24( 3): 375- 378. DOI: 10.3969/j.issn.1672-5069.2021.03.018. 刘彦荣, 王苗, 曾果, 等. MRI弥散加权成像对原发性硬化性胆管炎患者肝纤维化评估价值分析[J]. 实用肝脏病杂志, 2021, 24( 3): 375- 378. DOI: 10.3969/j.issn.1672-5069.2021.03.018.

Relative Articles

[1]	Yanhong YE, Lijian LU. Current research status of Gd-EOB-DTPA-enhanced MRI in evaluating liver reserve function in residual liver tissue after liver tumor surgery[J]. Journal of Clinical Hepatology, 2024, 40(2): 380-385. doi: 10.12449/JCH240226
[2]	Mu Rong, Lu LunGen. Advances in the application of magnetic resonance imaging in hepatic fat quantification in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1366-1369. doi: 10.3969/j.issn.1001-5256.2020.06.038
[3]	International Communication Group, Imaging Technology Society of Chinese Medical Association. Expert consensus on hepatobiliary specific contrast agent gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced MRI scanning scheme[J]. Journal of Clinical Hepatology, 2020, 36(3): 519-521. doi: 10.3969/j.issn.1001-5256.2020.03.008
[4]	Wang Hao, He Cheng, Chen Hao, Ou YangZhongMin, Liu ZhiQiang. Value of Gd-EOB-DTPA-enhanced MRI in the assessment of liver function in dogs with acute liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1576-1581. doi: 10.3969/j.issn.1001-5256.2019.07.030
[5]	Pan Qi, Luo ChunHai, Ma WanLing, Qu YuanFei, Wang JianRu, Chen Lin. Specific magnetic resonance imaging of vascular endothelial growth factor-C targeted molecular probe and its clinical significance in a rat model of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(7): 1492-1496. doi: 10.3969/j.issn.1001-5256.2018.07.025
[6]	Li RuoKun, Yan FuHua, Li Ke. Value of Gd-EOB-DPTA in the diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(7): 1378-1381. doi: 10.3969/j.issn.1001-5256.2018.07.003
[7]	Sun Yu, Zhang Nan, Hou Jie, Ma XiangHong, Wang Wei, Yang BenQiang. Value of Gd-EOB-DTPA-enhanced MRI in diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(1): 129-132. doi: 10.3969/j.issn.1001-5256.2018.01.026
[8]	Chen QiPing, Lin Su, Shi ZhenShan, Zhu YueYong, Li YouBing. A cost-effectiveness analysis of Gd-EOB-DTPA contrast-enhanced magnetic resonance imaging versus ultrasound in hepatocellular carcinoma screening[J]. Journal of Clinical Hepatology, 2018, 34(9): 1917-1920. doi: 10.3969/j.issn.1001-5256.2018.09.018
[9]	Luo YongHeng, Xiao EnHua. Role of functional magnetic resonance imaging in evaluating the therapeutic effect of transcatheter arterial chemoembolization in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(12): 2277-2281. doi: 10.3969/j.issn.1001-5256.2016.12.010
[10]	Yan FuHua. Research advances in computed tomography and magnetic resonance imaging findings of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(6): 1079-1082. doi: 10.3969/j.issn.1001-5256.2016.06.011
[11]	Wu Jie, Jing ZongLin. Research advances in MRI features and diagnosis of hepatocellular adenomas[J]. Journal of Clinical Hepatology, 2016, 32(10): 2012-2015. doi: 10.3969/j.issn.1001-5256.2016.10.045
[12]	Jiang JiaYun, Li XueSong, Ma KuanSheng. Application of hepatobiliary-specific MRI contrast agent Gd-EOB-DTPA in preoperative evaluation of hepatobiliary patients[J]. Journal of Clinical Hepatology, 2015, 31(6): 996-999. doi: 10.3969/j.issn.1001-5256.2015.06.042
[13]	Wang LiLi, Lei JunQiang, Guo JiGang, Yin Liang, Zhai YaNan, Li JinKui, Chen Hong, Guo ShunLin. Value of Gd-EOB-DTPA-enhanced MRI in assessing liver function[J]. Journal of Clinical Hepatology, 2015, 31(5): 749-753. doi: 10.3969/j.issn.1001-5256.2015.05.028
[14]	Huang RuiSui, Li Cheng, Gu Han, Jiao ZhiYun. Establishment of rat model of liver cirrhosis or liver cancer and its magnetic resonance images before and after superparamagnetic iron oxide enhancement[J]. Journal of Clinical Hepatology, 2013, 29(10): 769-774. doi: 10.3969/j.issn.1001-5256.2013.10.012
[15]	Gu Han, Li Cheng. Research progress in magnetic nanoparticles for magnetic resonance imaging and targeted therapy of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2013, 29(10): 740-743. doi: 10.3969/j.issn.1001-5256.2013.10.005
[16]	Feng HaiLong, Li CaiYing, Wang YingJie, Feng PingYong, Cui CaiXia. Contribution of diffusion weighted MR imaging in the differential diagnosis of focal hepatic lesions at 3T[J]. Journal of Clinical Hepatology, 2011, 27(4): 400-402.
[17]	Mai Jing, Gao YueQiu. The application of magnetic resonace elastography in the non-invasive diagnosis of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(3): 318-320+324.
[20]	Zhao GuoKu, Chen Kai, Zhou HongWei. MRI diagnostic value of liver adenoma[J]. Journal of Clinical Hepatology, 2004, 20(5): 291-292+321.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(7) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (455) PDF downloads(37)

Value of MRI biliary score and liver/muscle ratio in evaluating the pathological grade of liver fibrosis

DOI: 10.12449/JCH240413

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Value of MRI biliary score and liver/muscle ratio in evaluating the pathological grade of liver fibrosis

DOI: 10.12449/JCH240413

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content